Normal
0

false
false
false

EN-US
X-NONE
X-NONE

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin-top:0in;
mso-para-margin-right:0in;
mso-para-margin-bottom:8.0pt;
mso-para-margin-left:0in;
line-height:107%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:”Calibri”,sans-serif;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;}

Metformin may provide a long-term protective effect against
neurodegenerative diseases like Alzheimer’s and Parkinson’s, according to new
research.
Findings from a study of 
Veterans’ Affairs electronic medical records were presented at the
American Diabetes Association (ADA) 2016 Scientific Sessions by Qian Shi, a
PhD.
According to Ms. Shi, “For metformin exposure longer
than 2 years, we found a significant reduction in neurodegenerative
disease.…Metformin may be neuroprotective.”
These results were proven to be consistent even after
researchers controlled for kidney function, chronic renal disease, and other
diabetes medications.
The study population consisted of patients with type 2
diabetes who were older than 50 and who were receiving insulin treatment. They
were followed from the time of diagnosis until death or outcome.
In addition to renal function and other diabetes medications
patients were also controlled for age, gender, race, tobacco use, obesity as
well as history of other complications and comorbidities at baseline.

Metformin Linked to Lower Neurodegenerative Disease Risk. Medscape. Jun 11, 2016.

American Diabetes Association 2016 Scientific Sessions; June
11, 2016; New Orleans, Louisiana. Abstract 72-OR/72